How do you approach adjuvant comprehensive breast or chest wall RT for locally advanced breast cancer on a CDK 4/6 inhibitor?

Prospective data in this setting is limited. Retrospective and preclinical data with palliative RT and CDK 4/6 inhibitors have shown mixed results, with some showing skin and lung toxicities and others not. Adjuvant trials allowed concomitant use, but have not reported separately. My bias for PMRT i...